PrioThera Limited
Tuesday, 13 October 2020
ByrneWallace advise PrioThera Limited (PrioThera), an Irish clinical stage start-up in relation to its €30 million Series A fundraising to advance the development of mocravimod, a drug taken orally that activates cell receptors to trigger part of the body’s immune response against acute myeloid leukaemia. PrioThera, which is based in Dublin, acquired rights to mocravimod from Japan’s Kyorin Pharmaceutical Co. LTD. This financing round was led by Irish life sciences venture capital group Fountain Healthcare Partners, co-led by HealthCap (Stockholm, Sweden), with participation from Tekla Capital Management, LLC (Boston, Massachusetts) and EarlyBird Venture Capital (Berlin, Germany).
Founded in 2020, PrioThera was established specifically to hunt for cure for cancers of the blood, the bone marrow and lymph nodes, and states that mocravimod has already been extensively tested in multiple immunological models and has shown survival benefit in early clinical study evaluating acute myeloid leukaemia and acute lymphocytic leukaemia patients undergoing hematopoietic stem cell transplantation (HSCT).
The ByrneWallace team who advised on this transaction included Catherine Dowling (Partner, Corporate & Life Sciences).
For more information on this transaction and to view PrioThera’s press release click here.
